As lapatinib is administered to HER2-positive breast cancers with acquired resistance to trastuzumab in clinical setting, it is valuable to establish a trastuzumab/lapatinib-dual resistant cell line from a trastuzumab-resistant cell line. This evidence concerns the gene ERBB2 and breast cancer.